Kayne Anderson Rudnick Investment Management
PACB icon

Kayne Anderson Rudnick Investment Management’s Pacific Biosciences PACB Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,046
Closed -$12K – 1018
2024
Q3 		$12K Hold
7,046
– – ﹤0.01% 661
2024
Q2 		$9.65K Hold
7,046
– – ﹤0.01% 637
2024
Q1 		$26.4K Hold
7,046
– – ﹤0.01% 573
2023
Q4 		$69.1K Hold
7,046
– – ﹤0.01% 503
2023
Q3 		$58.8K Buy
+7,046
New +$80.5K ﹤0.01% 499

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's PACB Position: Q4 2024 in Review

Kayne Anderson Rudnick Investment Management sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 7,046 shares — an estimated $12K sold.

Kayne Anderson Rudnick Investment Management first reported a position in PACB in Q3 2023 and held it in 5 quarters. The position peaked at $69.1K in Q4 2023. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Kayne Anderson Rudnick Investment Management reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 7,046 Pacific Biosciences shares in Q4 2024, an estimated $12K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Pacific Biosciences in Q3 2023 and held it in 5 quarters.
  • Kayne Anderson Rudnick Investment Management's Pacific Biosciences position peaked at $69.1K in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.